Future development trends of Cabozantinib: from clinical application to new drug exploration

1. Overview of cabozantinib: the unique value of multi-target targeted drugs

Cabozantinib (Cabozantinib), as a multi-target tyrosine kinase inhibitor, has gradually become one of the key drugs in the global anti-cancer field in the past decade. Its unique mechanism of action not only inhibits tumor angiogenesis, but also interferes with the tumor microenvironment and metastasis-related pathways. Therefore, it has shown efficacy in a variety of malignant tumors such as renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). At present, international authoritative guidelines have listed it as a first-line or second-line recommended drug for multiple cancer types. Especially in the era of combined immunotherapy, cabozantinib's status is more stable.

2. Latest progress in cabozantinib indications

1. Renal cell carcinoma (RCC): It can be used as a single agent in advanced patients or in combination with the immune checkpoint inhibitor nivolumab. The first-line combination treatment model is believed to prolong patient survival and improve long-term quality of life.

2. Hepatocellular carcinoma (HCC): Mainly used for patients who have failed sorafenib treatment, providing new treatment opportunities for people who lack drug options.

3. Differentiated thyroid cancer (DTC): It is suitable for patients who are ineffective or intolerant to radioactive iodine, especially in children and adolescent patients.

4. Pancreatic neuroendocrine tumors (pNET): Applicable to adults and children aged 12 years and above with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET).

xa0

3. Clinical analysis of cabozantinib usage and dosage

Special attention should be paid to the relationship between cabozantinib administration and eating to avoid affecting drug absorption. The usual dose for adult patients is 60 mg daily, and for pediatric patients 12 years old and above who weigh less than40 kg, the usual dose is orally 40 mg once a day. In combination therapy, it is adjusted to 40mg to reduce adverse reactions. For pediatric patients, the dose is set based on body surface area (BSA). This precision medication strategy is in line with the international trend of "individualized treatment." In addition, it is necessary to pay attention to the risks related to surgery during the treatment process. It is clinically recommended to stop medication three weeks before surgery to reduce the risk of postoperative complications.

xa0

4. Mechanism of action: the scientific basis of multi-target inhibition

Unlike most single-target targeted drugs, cabozantinib acts on multiple signaling pathways at the same time. It can inhibit MET, VEGFR, AXL and other receptors related to angiogenesis and metastasis, thereby blocking the "fuel supply" of tumor growth. At the same time, it also has inhibitory effects on RET, ROS1, FLT-3 and other molecules, further expanding the scope of clinical application. This "multi-target coverage" mechanism not only improves treatment efficiency, but also reduces drug resistance problems that may arise from single-target treatment.

xa0

xa0

5. Clinical efficacy: global research and real-world data

According to data from multiple overseas studies, cabozantinib can improve progression-free survival (PFS) and overall survival (OS) in patients with advanced RCC and is more effective than traditional targeted drugs. In hepatocellular carcinoma, cabozantinib still shows the potential to prolong survival despite the complex underlying conditions of patients. In the treatment of DTC, drugs are particularly critical for patients with radioactive iodine resistance, providing an effective solution for people who originally lacked drug options. These studies continue to strengthen its position as a global "multi-cancer" treatment drug.

xa0

6. Key points of adverse reactions and safety management

Similar to other targeted drugs, the adverse reactions of cabozantinib are mainly concentrated in the digestive tract and skin reactions, such as diarrhea, nausea, PPE syndrome, etc. Some patients may develop hypertension or stomatitis, which requires dynamic monitoring and intervention during treatment. It is worth noting that the drug has also been reported to be associated with aneurysms and vascular dissection after its marketing, so clinicians need to be more cautious when using it in high-risk groups.

xa0

7. International market prices and supply of generic drugs

The original drug cabozantinib has been fully launched in Europe, the United States and Japan. It is relatively expensive, with monthly treatment costs ranging from tens of thousands of yuan. In the Hong Kong market, common 20mg, 40mg and 60mg tablets are generally priced between NT$30,000 and NT$50,000. At the same time, the price of generic drugs in places such as India, Bangladesh and Laos has been significantly reduced, and each box may only cost thousands or even hundreds of yuan, which has greatly eased the financial burden of some patients. This price difference has also promoted the demand for cross-border drug purchases and has become a hot spot in the current international pharmaceutical market.

xa0

8. Medication accessibility issues in the context of current events

In recent years, with the rapid development of global tumor immunotherapy, combination treatment models have gradually become mainstream. The combination of cabozantinib and PD-1 inhibitors has opened a new treatment channel for many advanced patients. On the other hand, international pharmaceutical supply chains and price fluctuations are also affecting patient accessibility. For example, the epidemic and geopolitics have affected the supply of raw materials and the cross-border circulation of drugs, resulting in short-term drug shortages in some regions. How to ensure patients' long-term and stable medication needs has become an urgent issue for medical policy and market supervision.

xa0

9. Future research directions and development trends

Currently, research on cabozantinib is still expanding. In addition to its existing indications, its research in prostate cancer, pancreatic cancer and some rare tumors also shows potential. Scientists are exploring its combination with other immune drugs, chemotherapy or radiotherapy in order to further extend patient survival benefits. At the same time, with the advancement of molecular diagnostic technology, cabozantinib is expected to be selected more accurately based on the patient's genetic characteristics in the future, making it truly a "customized anti-cancer weapon."

xa0

10. Summary and Outlook

Cabozantinib is not only a single drug, but also an important representative of a new era of multi-cancer treatment. Its multi-target mechanism, multi-indication coverage and application in immune combination therapy will continue to occupy a core position in the field of oncology in the future. For patients, how to reduce the financial burden while ensuring therapeutic efficacy is currently the most concerning issue. With the popularity of generic drugs and policy support, the accessibility of cabozantinib is expected to continue to increase, allowing more patients to benefit from it.

xa0

Overseas Reference Materials

Exelixis: Cabozantinib (Cabometyx) Official Information

FDA: Cabozantinib Prescribing Information

ESMO Guidelines on Kidney, Liver, Thyroid Cancers

PubMed: Recent clinical trials on Cabozantinib